| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $45,415 across 5 awards. 36C24225P0099 SURGICAL IMPLANT; 36C26126P0059 PROSTHETICS - MESH; 36C25025P1056 OVITEX 1S PERMANENT 25X30 | Qwen corre… |
| GPOS |
GPOS |
90%
|
We have contracted with three national GPOs covering our OviTex and OviTex PRS products |
| HOSPITALS |
HOSPITALS |
90%
|
A significant portion of the Company’s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals or other surgical facilities. |
| SURGICAL-FACILITIES |
SURGICAL-FACILITIES |
90%
|
A significant portion of the Company’s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals or other surgical facilities. |
| HEALTHCARE-SYSTEMS |
HEALTHCARE-SYSTEMS |
85%
|
Our OviTex products are sold at prices approximately 20% to 40% lower than other biologic matrices and resorbable synthetic mesh |
| THIRD-PARTY-PAYORS |
THIRD-PARTY-PAYORS |
85%
|
The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. |
| BDX |
Becton, Dickinson and Company |
72%
|
Reciprocal relationship from BDX graph: Reciprocal relationship from TELA graph: Reciprocal relationship from BDX graph: Reciprocal relationship from TELA graph: cost as a percentage of Aroa’s cost o… |
| BDX |
Becton, Dickinson and Company |
72%
|
cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal to 27% of our net sales of our OviTex and OviTex PRS products, with the exception … |
| MDT |
Medtronic plc |
72%
|
Reciprocal relationship from MDT graph: Reciprocal relationship from TELA graph: Reciprocal relationship from MDT graph: Reciprocal relationship from TELA graph: rgeon adoption of biologic and biosur… |
| MDT |
Medtronic plc |
72%
|
rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical technology companies such as Orthovita Inc., Stryker Corporation, OraSure Technolo… |
| MDXG |
MiMedx Group, Inc. |
72%
|
cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal to 27% of our net sales of our OviTex and OviTex PRS products, with the exception … |
| MDXG |
MiMedx Group, Inc. |
72%
|
Reciprocal relationship from MDXG graph: Reciprocal relationship from TELA graph: Reciprocal relationship from MDXG graph: Reciprocal relationship from TELA graph: Reciprocal relationship from MDXG g… |
| OSUR |
OraSure Technologies, Inc. |
72%
|
rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical technology companies such as Orthovita Inc., Stryker Corporation, OraSure Technolo… |
| OSUR |
OraSure Technologies, Inc. |
72%
|
Reciprocal relationship from OSUR graph: Reciprocal relationship from TELA graph: rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical … |
| ADVANCED-MEDICAL-SOLUTIONS-LIMITED |
ADVANCED-MEDICAL-SOLUTIONS-LIMITED |
62%
|
ts and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms o… |
| AROA-BIOSURGERY-LTD |
AROA-BIOSURGERY-LTD |
62%
|
of such terms, and other similar expressions although not all forward-looking statements contain these identifying words. You should understand that the following important factors could affect our… |
| C-R-BARD-INC |
C-R-BARD-INC |
62%
|
13485 compliant facility in Auckland, New Zealand. We purchase product from Aroa at a fixed transfer cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting … |
| LIFECELL-CORPORATION |
LIFECELL-CORPORATION |
62%
|
13485 compliant facility in Auckland, New Zealand. We purchase product from Aroa at a fixed transfer cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting … |
| ORTHOVITA-INC-STRYKER-CORPORATION-ORASURE-TECHNO |
ORTHOVITA-INC-STRYKER-CORPORATION-ORASURE-TECHNO |
62%
|
and commercialization of multiple new products, including driving surgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical technology com… |
| PERCEPTIVE-CREDIT-HOLDINGS |
PERCEPTIVE-CREDIT-HOLDINGS |
62%
|
know of or that we currently think are immaterial may also arise and materially affect our business. The realization of any of these risks could have a material adverse effect on our business, financ… |
